J&J wins trial in talc product liability lawsuits

The verdict came after 3 straight prior jury verdicts against Johnson & Johnson

Johnson & Johnson
Johnson & Johnson <b>(Image: Reuters)</b>
Reuters
Last Updated : Mar 04 2017 | 4:31 AM IST

Johnson & Johnson said on Friday that a state court jury in Missouri had returned a verdict in its favour in the latest trial to arise out of thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer.

The jury sided with Johnson & Johnson and talc supplier Imerys Talc in a lawsuit by Tennessee resident Nora Daniels, who alleged that she used J&J Baby Powder for 36 years and was diagnosed with ovarian cancer in 2013.

The verdict came after three straight prior jury verdicts in St Louis against J&J awarding plaintiffs a combined $195 million. More than 2,500 lawsuits are pending in state court in St Louis.

"The jury's decision is consistent with the science, research, clinical evidence and decades of studies by medical experts around the world that continue to support the safety of cosmetic talc," Johnson & Johnson said in a statement.

Imerys in a statement thanked the jury "for following the science that establishes the safety of talc."

Ted Meadows, a lawyer for Daniels, in a statement said he was disappointed by the verdict.

"We continue to maintain that the association between genital talc usage and ovarian cancer remains an issue of public health and demands that consumers be warned of the specific risks," he said in a statement.

Plaintiffs have accused J&J of failing for years to warn that talc was linked to an increased risk for ovarian cancer. J&J has said it acted properly in developing and marketing the products.

In February 2016, a Missouri state jury ordered J&J to pay $72 million to the family of a woman who died from ovarian cancer after years of using talc powder for feminine hygiene.

In May, another jury in Missouri returned $55 million to a woman who said the company's talc-powder products caused her to develop ovarian cancer. J&J was subsequently hit with a third verdict in October for $67.5 million.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 04 2017 | 3:48 AM IST

Next Story